Experienced in B-Cell Lymphoma

Rong J. Tao

Dongchuan Road, 
Shanghai, CN 
Experienced in B-Cell Lymphoma
Dongchuan Road, 
Shanghai, CN 
OverviewLocationsClinical Research

Overview

Rong Tao practices in Shanghai, China. Tao is rated as an Experienced expert by MediFind in the treatment of B-Cell Lymphoma. Their top areas of expertise are Non-Hodgkin Lymphoma, B-Cell Lymphoma, Heart Failure, Laminectomy, and Bone Marrow Transplant.

Their clinical research consists of co-authoring 71 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 6 articles in the study of B-Cell Lymphoma.

Locations

Dongchuan Road, Shanghai, 200240, China
Other Locations
No. 800 Dongchuan Road, Shanghai, 200240, China
No.800 Dongchuan Road, Shanghai, 200240, China
1665 Kongjiang Rd, Shanghai, 200092, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A Phase 2, Open-Label Study of BGB-A317 in Patients With Relapsed or Refractory Mature T- and NK-cell Neoplasms
A Phase 2, Open-Label Study of BGB-A317 in Patients With Relapsed or Refractory Mature T- and NK-cell Neoplasms
Enrollment Status: Completed
Publish Date: October 26, 2024
Intervention Type: Drug
Study Drug: Tislelizumab
Study Phase: Phase 2
A Phase I Open-Label Study of the Safety and Tolerability of ATG-019, a Dual Inhibitor of PAK4 and NAMPT, in Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma
A Phase I Open-Label Study of the Safety and Tolerability of ATG-019, a Dual Inhibitor of PAK4 and NAMPT, in Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma
Enrollment Status: Terminated
Publish Date: April 30, 2024
Intervention Type: Combination product, Drug
Study Drugs: ATG-019 PAK4/NAMPT Dual Inhibitor, Niacin
Study Phase: Phase 1
Efficacy and Safety of Tislelizumab Combined Treatment in Refractory Natural Killer/T-cell Lymphoma
Efficacy and Safety of Tislelizumab Combined Treatment in Refractory Natural Killer/T-cell Lymphoma
Enrollment Status: Completed
Publish Date: March 04, 2024
Intervention Type: Drug
Study Phase: Not Applicable
View 2 Less Clinical Trials

71 Total Publications

Epcoritamab, lenalidomide, and rituximab versus lenalidomide and rituximab for relapsed or refractory follicular lymphoma (EPCORE FL-1): a global, open-label, randomised, phase 3 trial.
Epcoritamab, lenalidomide, and rituximab versus lenalidomide and rituximab for relapsed or refractory follicular lymphoma (EPCORE FL-1): a global, open-label, randomised, phase 3 trial.
Journal: Lancet (London, England)
Published: October 24, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Tao's expertise for a condition
ConditionClose
        View All 19 Experienced Conditions
        Want to save this expert for later?
        Sign Up
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile